Is VKTX or VRDN more undervalued in 2026?

CirclFi compares Viking Therapeutics, Inc. (VKTX) and Viridian Therapeutics, Inc. (VRDN) using 13 institutional-grade valuation models. VKTX has a Quality of Company score of 4.7/10 while VRDN scores 6.3/10.

Which is a better buy — VKTX or VRDN?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do VKTX and VRDN valuations compare?

VKTX at $32.19 and VRDN at $17.45 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

VKTX vs VRDN Valuation Comparison 2026 — Intrinsic Value Analysis

VKTX

Biotechnology

Viking Therapeutics, Inc.

Quality

4.7

out of 10

Value Trap

SAFE

Price

$32.19

Last close

Models

10/13

Active

VRDN

Biotechnology

Viridian Therapeutics, Inc.

Quality

6.3

out of 10

Value Trap

SAFE

Price

$17.45

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	VKTX Fair Value	VKTX Upside	VRDN Fair Value	VRDN Upside
Bayesian DCF	Intrinsic	$10.25	-68.1%	$5.55	-68.2%
Earnings Power Value	Intrinsic	$14.75	-55.0%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$5.06	-84.3%	$5.82	-66.6%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for VKTX vs VRDN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

VKTX vs VRDN — Which Stock Is More Undervalued?

VRDN scores higher with a 6.3/10 quality rating vs VKTX's 4.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Viking Therapeutics, Inc. (VKTX) and Viridian Therapeutics, Inc. (VRDN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

VKTX currently trades at $32.19 with a QOC of 4.7/10, while VRDN trades at $17.45 with a QOC of 6.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).